What development phase is avilamycin in?

avilamycin is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

avilamycin

FDA-approved active Quality 6/100

Avilamycin is a marketed antibiotic that inhibits bacterial protein synthesis, leading to cell death. Its key strength lies in its mechanism of action, which effectively prevents bacteria from producing essential proteins. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic name	avilamycin
Therapeutic area	Infectious Disease
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

avilamycin CI brief — competitive landscape report
avilamycin updates RSS · CI watch RSS
portfolio CI